Neuron23, Inc., a South San Francisco, CA, and Munich, Germany-based early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, has launched backed by a combined $113.5m Series A and B financing.
The round was comprised of $33.5m Series A financing from Westlake Village BioPartners and Kleiner Perkins, and $80m Series B financing led by Redmile Group. Additional Series B investors included Westlake Village BioPartners, Kleiner Perkins, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners, Perceptive Advisors, and Surveyor Capital (a Citadel company). In connection with the Series A and B rounds, Beth Seidenberg, Amrit Nagpal (Redmile Group), Kevin Raidy (Cowen Healthcare Investments), Michael Almstetter (Origenis), and Nancy Stagliano serve on the Board of Directors.